B7-H4 presents an attractive target for cancer immunotherapy, with potential blockade via various mechanisms, including monoclonal antibodies (mAbs), single chain fragment variables(scFv), antibody-drug conjugates (ADCs), CD3 bispecific antibodies (BiTEs), and chimeric antigen receptor T cells (CAR-Ts) in OC (70–73). This evidence concerns the gene VTCN1 and cancer.